Latest News
-
Milestone for Queens GM2 trial
TSHA-101 gene therapy clinical trial application (CTA) approved in Canada Read More -
-
- 1
- 2
- 3
›
‹
NTSAD leads the worldwide fight to treat and cure Tay-Sachs, Canavan, GM1, and Sandhoff diseases by driving research, forging collaboration, and fostering community. Supporting families is the center of everything we do.
- Default
- Title
- Date
- Random
